Core Insights - Paysign's patient affordability business was the primary driver of growth in 2025, with segment revenue increasing by 168% year-over-year to $33.9 million from $12.7 million, and processed claims rising approximately 79% [1][6] Financial Performance - For the full year 2025, Paysign reported a revenue increase of 40.5% to $82.0 million, with net income rising 98% to $7.6 million and adjusted EBITDA increasing 107% to $19.9 million [3][7] - Operating expenses totaled $41.4 million, up 32.6%, which was below the revenue growth rate, while gross margin improved to 59.4% from 55.1% a year earlier [2] - Operating margin rose to 9% from 1.7% in the prior year, attributed to scalability in the cost structure as the patient affordability business grew [2][3] Business Segments - The patient affordability platform delivered nearly $1 billion in assistance to over 840,000 individuals in 2025, with dynamic rules saving clients over $325 million [6][7] - The plasma donor compensation business generated $45.6 million in revenue for 2025, reflecting a 4% increase from $43.9 million in 2024, supported by the addition of 115 net plasma centers [11] Future Outlook - Paysign expects 2026 revenue to be between $106.5 million and $110.5 million, representing 30% to 35% growth, with adjusted EBITDA projected at $30 million to $33 million [5][16] - The company anticipates net income for 2026 to be between $13 million and $16 million, or $0.21 to $0.26 per diluted share [17] Strategic Initiatives - Paysign added 55 programs in 2025, ending the year with 131 active programs across more than 70 patient affordability clients, including relationships with six of the top 10 U.S. pharmaceutical manufacturers [8][6] - The company is awaiting FDA 510(k) review for its donor management system and expects to hear back within the next 60 days [13] Market Position - The company maintains a strong balance sheet, exiting 2025 with $21.1 million in cash and no bank debt, indicating robust financial health [15]

Financial Data and Key Metrics Changes - Revenue grew 41% year over year to $18.6 million, up from $13.2 million in Q1 of last year [5] - Net income surged to $2.59 million, a 737% increase over Q1 2024 [5] - Adjusted EBITDA jumped 193% to $4.9 million, with gross margin expanding over 10 points to 62.9% [5][6] Business Line Data and Key Metrics Changes - Patient Affordability business revenues rose 261% year over year to $8.6 million, with claims processed growing by more than 160% [6] - Plasma donor compensation revenue decreased 9.2% to $9.4 million, with revenue per plasma center declining to $6,517 [10][14] Market Data and Key Metrics Changes - The Patient Affordability segment accounted for 46.3% of quarterly revenues, a significant increase from 18.1% in the same period last year [15] - The company ended the quarter with 484 plasma centers, adding four new centers during the period [10][14] Company Strategy and Development Direction - The acquisition of Gamma Innovation is expected to enhance the tech stack and offer a full front-end engagement platform integrated with core payment solutions [11][12] - The company aims to unlock additional revenue streams and expand its total addressable market beyond the plasma sector into broader pharmaceutical and healthcare sectors [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory and commitment to delivering long-term value to shareholders [13] - The company expects patient affordability revenue to more than double again in 2025 based on current pipeline and results [8] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt [17] - Full-year gross profit margins are expected to be between 62% to 64%, reflecting stable margins in the plasma business and increased contributions from the higher-margin pharma patient affordability business [18] Q&A Session Summary - No questions were raised during the Q&A session [21]

Financial Data and Key Metrics Changes - Revenue grew 41% year over year to $18.6 million, up from $13.2 million in Q1 2024 [5][16] - Net income surged to $2.59 million, a 737% increase over Q1 2024 [5][16] - Adjusted EBITDA jumped 193% to $4.9 million, with gross margin expanding over 10 points to 62.9% [5][16] Business Line Data and Key Metrics Changes - Patient Affordability business revenues rose 261% year over year to $8.6 million, with claims processed growing by more than 160% [6][15] - Plasma donor compensation revenue decreased 9.2% to $9.4 million, with revenue per plasma center declining to $6,517 [9][14] Market Data and Key Metrics Changes - The Patient Affordability segment accounted for 46.3% of quarterly revenues, a significant increase from 18.1% in the same period last year [15] - The company added 14 new programs in the Patient Affordability business, totaling 90 active programs [6][15] Company Strategy and Development Direction - The company is investing in innovation, including the acquisition of Gamma Innovation to enhance its tech stack and expand its offerings in the plasma market [11][12] - The integrated model from the Gamma acquisition is expected to unlock additional revenue streams and strengthen competitive differentiation [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the growth trajectory and commitment to delivering long-term value to shareholders [13] - The company expects patient affordability revenue to more than double again in 2025 based on current pipeline trends [8] Other Important Information - The company exited the quarter with $6.9 million in unrestricted cash and zero debt [17] - Full year gross profit margins are expected to be between 62% to 64% [19] Q&A Session Summary - No questions were raised during the Q&A session, and the call concluded without further inquiries [22]